EANS-Adhoc: LifeWatch announces joint development of new breakthrough test for its wireless cardiac monitoring platform (with document)
Ein Dokument
-------------------------------------------------------------------------------- ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- New Products/LifeWatch AG 24.02.2012 The testing technology will be deployed on LifeWatch wireless cardiac monitors in coming months. Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss Exchange:LIFE), the leading wireless cardiac monitoring service provider in the U.S., announced today the joint development of additional Sympathetic and Parasympathetic testing with the ANSAR Group. For the first time in the wireless cardiac monitoring industry, the treating physician will be able to measure individual parasympathetic and sympathetic responses of their patient. This information will be significant in providing additional clinical data for patients with Atrial Fibrillation, Syncope (fainting), Congestive Heart Failure, Cardiac Autonomic Neuropathy (associated with increased risk of mortality and morbidity) and Hypertension. These conditions together affect an estimated 99 million Americans1. An additional subset of patients who could benefit from this test includes millions of Americans who are currently prescribed Beta blockers. "The Ansar test integrated with our ACT cardiac telemetry platform is a very important technological advance", stated Dr. Yacov Geva, Chairman and CEO of LifeWatch AG. "For the first time ever, a physician will be provided with invaluable clinical information about a patient's sympathetic and parasympathetic nervous system in a comprehensive arrhythmia report via an outpatient cardiac monitoring platform. The data generated from the Ansar test and LifeStar ACT cardiac monitor will assist in guiding therapy. Physicians will be able to diagnose vasovagal or neurocardiogenic syncope, orthostasis, arrhythmia or palpitations caused by surges in the parasympathetic or sympathetic tone with the LifeWatch ACT monitor. This has the potential to improve patient outcomes, reduce medication loads, hospitalizations, unnecessary deaths and overall healthcare costs. It is an honor for LifeWatch to be able to empower physicians with this capability." The Ansar parasympathetic and sympathetic response monitoring test allows for the differential diagnosis of three main causes of syncope (neurogenic, vasovagal and cardiogenic), and other causes of dizziness (including orthostasis and arrhythmia). These individual measurements can be recorded preceding an arrhythmic event, which will provide physicians with clear and precise documentation of the causes of underlying syncope, dizziness, arrhythmia, chest pain, or sleep disordered cardiac disturbances, etc., and aid the physician in the differential diagnosis and guiding therapy. The easy-to-use test utilizes a LifeStar ACT wireless cardiac monitor enabling real-time viewing of the ECG before the patient is sent home for continued arrhythmia monitoring. The Ansar test, which is reimbursable, includes physiological parameters equivalent to a head-up tilt table test, and has demonstrated higher rates of specificity and sensitivity2. This test is encouraged by many of the leading professional medical societies in the United States, including the AHA, ADA, JDFI, AAN, AAFP, NIH. Published, peer-reviewed, parasympathetic and sympathetic response testing data shows how to optimize therapy for many difficult to treat conditions, including Atrial Fibrillation, Heart Failure, Hypertension, Dizziness (including syncope) and sleep disorders. This technology will be available in the US in the following months. Sources: 1. Circulation 2012, 125:e2-e220, 2. Am Heart J 1997;134:316-20. About LifeWatch AG: LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless remote patient monitoring services. LifeWatch services cater to individuals, ranging from high-risk and chronically ill patients, to consumers of health and wellness products. LifeWatch has subsidiaries in the United States, the Netherlands, Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is the parent company of LifeWatch Services Inc., a leading US-based cardiac monitoring service provider, and manufacturer of telecardiology products. LifeWatch is also introducing a new program for Home Sleep Testing of Obstructive Sleep Apnea (OSA) patients under the brand name NiteWatch. For additional information, please visit http://www.lifewatch.com. Sign-up for customized E-mail alerts and documentation requests is available at http://production.investis.com/lifewatch/alert-service/ This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, business strategy and plans and objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. LifeWatch AG has based these forward-looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short term and long term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to LifeWatch AG at the time of the issue of this press release. LifeWatch AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER. Attachments with Announcement: ---------------------------------------------- http://resources.euroadhoc.com/us/9HSfZYNF Further inquiry note: Sensus Investor and Public Relations GmbH, Zürich: Tel+41 433665511 | Fax+41 43 366 55 12|Email lifewatch@sensus.ch end of announcement euro adhoc -------------------------------------------------------------------------------- Attachments with Announcement: ---------------------------------------------- http://resources.euroadhoc.com/us/9HSfZYNF issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: SIX Swiss Exchange language: English